Proto Axiom operates as a hands-on biomedical technology incubator, providing technical oversight, administrative support, future financing and research assistance to early-stage biotech projects. The firm emphasizes onshoring Australia’s scientific capacity and keeping downstream IP and economic benefits in-country. Recent activities include a led investment of $2 million in UNSW spin-out Swan Genomics and continued support for portfolio company Endo Axiom as it approaches first-in-human trials for an oral insulin platform. Proto Axiom positions itself as a first-in-country, holistic enterprise model rather than a traditional fund, and runs programming such as the Challenger Summit offering over $250,000 in unencumbered grant financing. Management says the capital will be used to continue strategically investing in and supporting Australia’s best science.

Total raised

$20M

Funding rounds

1

Latest round

Series B

Latest activity

Aug 2024